• 出版社/出版日：Mordor Intelligence / 2022年1月
|Single User||￥627,000 (USD4,750)||▷ お問い合わせ|
|Site Licence||￥858,000 (USD6,500)||▷ お問い合わせ|
|Corporate License||￥1,155,000 (USD8,750)||▷ お問い合わせ|
・競争状況（Portola Pharmaceuticals Inc.、Boehringer Ingelheim GmbH、CSL Behring Limited、...）
The anticoagulant reversal drugs market was valued at approximately USD 985 million in 2020, and it is expected to witness a revenue of USD 1,945 million in 2026, with a CAGR of 12.01% over the forecast period, 2021-2026.
The impact of COVID-19 on the anticoagulant reversal drugs market is expected to be significant, owing to the increasing pace of research activities on COVID-19 infection. For instance, as per the research article published in the American Journal of Cardiovascular Drugs, 2020, more than 10 clinical trials are in progress to evaluate the potential of factor Xa inhibitors in COVID-19 patients, and research on strategies for the parenteral administration of these drugs are worked upon to be used in critically ill COVID-19 patients. Thus, the COVID-19 pandemic is expected to have a direct and indirect impact on the studied market.
The major factors driving the market are a rise in the global prevalence of multiple cardiovascular indications, atrial fibrillation, an increase in intracranial and gastrointestinal hemorrhages, and the increasing geriatric population. According to the World Health Organization, an estimated 17.9 million people die due to cardiovascular diseases worldwide, each year. This represents 35% of global deaths. Additionally, 85% of these cardiovascular disease deaths are due to heart attack and stroke.
Also, according to the “Global Health And Wellness Report”, about 40% of the adult population in the United States were diagnosed with a cardiovascular condition in 2018. Similarly, there were around 7.4 million people living with heart and circulatory diseases in the United Kingdom, and more than 43,000 people under the age of 75 in the United Kingdom die from heart and circulatory diseases each year, as per the British Heart Foundation Centre, 2018 report. Moreover, as per the estimates of the Heart Disease and Stroke Statistics 2019, the lifetime risk of atrial fibrillation recently has been estimated to be approximately 1 in 3 among whites in the United States. Hence, the growing burden of cardiovascular diseases globally is expected to be a major factor for the increasing demand for anticoagulant reversal drugs, which may drive the market growth in the coming years.
Few more factors play a pivotal role in taking the market to the next level, such as approval of blockbuster drugs in recent years and the presence of a strong pipeline of products within the key players. However, the increased prices of most of the drugs bearing patents may restrain the market in the emerging economies during the forecast period.
Key Market Trends
The Coagulation Factors Segment is Expected to Hold the Largest Market Share
Coagulation factors are the proteins in the blood that control bleeding and comprise various coagulation factors in the blood.
According to the research article published in the Lancet, 2020, coagulopathy of varying severity was observed in most COVID-19 infected patients, which was characterized by increased D-dimer levels and fibrinogen or fibrin degradation products, along with abnormal measurements in the prothrombin time, acute partial thromboplastin time, and platelet counts. Hence, thorough research on various factors affecting the bleeding and coagulation among COVID-19 patients has to be carried out to understand the pathophysiology of the causal organism. Hence, COVID-19 is expected to impact the studied segment during the pandemic.
Andexxa is the first and only approved drug for the reversal of the effect of coagulation factor Xa inhibitors in adult patients. Portola Pharmaceuticals launched Andexxa in 2018, which has contributed to the major share of the company’s revenue. For the financial year 2019, Andexxa generated a revenue of USD 104.5 million for Portola Pharmaceuticals Inc., which was a major share in the company’s revenue for 2019. Additionally, the company has strategic plans for the global expansion of the product such as supporting its commercial marketing partners, Bristol-Meyers Squibb Company and Pfizer Inc., to accelerate the development and commercialization of Andexxa for the Japanese market by 2020. Thus, the increasing research activities in the development of new products by companies in the anticoagulant domain are expected to drive the growth of the studied segment over the forecast period.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America is expected to dominate the overall anticoagulant reversal drugs market throughout the forecast period. The high growth of the studied market in North America is due to factors such as the availability of direct reimbursement policies and the availability of advanced healthcare infrastructure in the region.
The COVID-19 impact on the studied market is expected to be significant in the region owing to the emergence of the relation between COVID-19 infection and blood disorders. For instance, according to the research article published by Harvard Medical School, in the American Journal of Hematology, 2020, the COVID-19 infected patients who were admitted with severe complications associated with the viral infection were found to exhibit high levels of blood-clotting protein Factor V, which could eventually lead to the development of blood clots in various organs.
In the North American region, the United States holds the largest market share due to the accelerated drug approval initiative by the USFDA, and the initiation of various prevention programs and awareness workshops for blood disorders by the Centers for Disease Control and Prevention, which is expected to drive the market growth in this region. Also, the high prevalence of cardiovascular diseases in the United States drives the studied market. According to the American Heart Association, every 40 seconds, an American will have a myocardial infarction, and coronary events are estimated to occur in about 1,055,000 individuals, including 720,000 new and 335,000 recurrent coronary events in 2019 in the United States.
Additionally, several key players of the studied market have their base in the United States and are expected to explore the market through R&D activities and product approvals. Thus, given the aforementioned factors, the anticoagulant reversal drugs market is anticipated to grow significantly over the forecast period in North America.
The anticoagulant reversal drugs market is consolidated and consists of few major players. The key players of the studied market include Pfizer Inc., Boehringer Ingelheim GmbH, CSL Behring Limited, Portola Pharmaceuticals Inc., and Octapharma AG, among others. Some prominent players are vigorously making acquisitions with other companies to consolidate their market positions across the globe, while others are launching generic products, along with increasing investments in research and development activities. For instance, in December 2020, OctaPharma USA presented the results of clinical research that was performed to evaluate the safety and efficacy of fibryga, a Human Fibrinogen Lyophilized Powder for Reconstitution, indicated for intravenous use in the treatment of congenital and acquired bleeding disorders, in the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Geriatric Population and Growing Blood Disorders
4.2.2 New Product Launches due to Accelerated Drug Approval Initiative by USFDA
4.3 Market Restraints
4.3.1 Stringent Regulatory Reforms due to Severe Risks Associated with the Reversal of Anticoagulation
4.3.2 Higher Challenges in Development Stage and Expensive Patented Products
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Prothrombin Complex Concentrates
5.1.2 Coagulation Factors
5.1.3 Monoclonal Antibodies
5.1.5 Other Drug Classes
5.2 By End User
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Other End Users
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.3.5 South America
184.108.40.206 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Portola Pharmaceuticals Inc.
6.1.2 Boehringer Ingelheim GmbH
6.1.3 CSL Behring Limited
6.1.4 Pfizer Inc.
6.1.5 Octapharma AG
6.1.6 Bausch Health Companies Inc.
6.1.7 Amneal Pharmaceuticals Inc.
6.1.8 Fresenius Kabi AG
6.1.9 Perosphere Pharmaceuticals Inc.
6.1.10 Ferring Pharmaceuticals Inc.
6.1.11 Midas Pharma GmbH
6.1.12 Healthy Life Pharma Pvt. Ltd
6.1.13 Pharma Cure Laboratories
6.1.14 Nischi Lifesciences
7 MARKET OPPORTUNITIES AND FUTURE TRENDS